United States Patent and Trademark Office

Hexagon US Federal Receives Trademark Registration from USPTO for ARTEMIS Geospatial Solution

Retrieved on: 
Monday, July 24, 2023
Technology, Engineering, Professional Services, Software, Manufacturing, Networks, Government Technology, Data Analytics, Data Management, Defense, Patent, Partnership, ARTEMIS, United States Patent and Trademark Office, United States Department of Defense, Intelligence, DIU, Federal, Blue, Administration, Federation, TAC, Collection

Hexagon US Federal has received an official trademark registration for the ARTEMIS solution from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • Hexagon US Federal has received an official trademark registration for the ARTEMIS solution from the United States Patent and Trademark Office (USPTO).
  • ARTEMIS (Aerial Reconnaissance Tactical Edge Mapping Imagery System) is a joint solution with our partners at Tough Stump Technologies and AgEagle.
  • “The trademark registration is the latest in an exciting series of milestones for ARTEMIS,” said Tammer Olibah, CEO & President of Hexagon US Federal.
  • “We are proud of this achievement, which will enable us to continue bringing our cutting-edge ARTEMIS geospatial solution to users in a variety of mission-critical spaces.”
    In 2021, Hexagon US Federal began a strategic effort to make ARTEMIS more easily available to defense, federal civilian, and public safety customers.

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Retrieved on: 
Wednesday, July 19, 2023
1836 U.S. Patent Office fire, Patent, Intellectual property, Heart failure, Prevalence, United States Patent and Trademark Office, Coronavirus Scientific Advisory Board, IP, Patient, FDA, Therapy, Pulmonary hypertension, Pharmaceutical industry

The issued patent (U.S. Patent No.

Key Points: 
  • The issued patent (U.S. Patent No.
  • 11,701,355) covers the use of oral levosimendan for the treatment of PH-HFpEF and provides exclusivity through December 2040.
  • The ‘355 patent further builds upon the Company’s substantial IP, which also includes issued U.S. patents for the use of intravenous (U.S. Patent No.
  • This is the most commonly seen patient in pulmonary hypertension referral centers, and yet not a single therapy has been approved for them.

Taco John's® to Share Taco Tuesday; Issues Challenge to Competitors (and LeB***) to Support Workers, Not Lawyers

Retrieved on: 
Tuesday, July 18, 2023
Taco John's, Patent, Injury, Friends, Parent, United States Patent and Trademark Office, Taco Tuesday, Cheese, Lawyer, Movement, Taco Bell, LEB, Child, Box, Hotel Employees and Restaurant Employees Union, CORE, Death, Mouth, Fast food, Taco

CHEYENNE, Wyo., July 18, 2023 /PRNewswire/ -- Taco John's, the home of Taco Tuesday for more than 40 years, will abandon the United States Patent and Trademark Office registration for its servicemark on the popular food holiday Tuesday, July 18.

Key Points: 
  • Taco John's, the home of Taco Tuesday for more than 40 years, will abandon the food holiday trademark today.
  • "As we've said before, we're lovers, not fighters, at Taco John's.
  • We also invite Del Taco, Taco Bueno, Taco Cabana, Jack In The Box and mom and pop taco shops across the country that intend to use Taco Tuesday in the future to join us in this movement to support working families and donate to CORE."
  • Taco John's also encourages noted taco lover, Taco Bell spokesperson and prolific trademark owner LeB*** Ja*** to do his part by donating any fees he received from the latest multi-million-dollar Taco Bell Taco Tuesday ad campaign to CORE.

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

Retrieved on: 
Tuesday, July 18, 2023
United States Patent and Trademark Office, Patent, ECOR, ElectroCore, United States patent law, 3D printing

ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent related to non-invasive nerve stimulation with mobile devices.

Key Points: 
  • ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent related to non-invasive nerve stimulation with mobile devices.
  • U.S. Patent No.
  • “electroCore continues to broaden its intellectual property portfolio which consists of over 200 patents and patent applications,” stated Dan Goldberger, Chief Executive Officer of electroCore.
  • “Over the last few years, electroCore has compiled a robust patent portfolio covering the use of mobile devices to operate a nerve stimulator which we look forward to leveraging in our new suite of products and devices.”

ThermoGenesis Expands Board of Directors with the Appointments of Dr. Biao Xi and Dr. James Xu

Retrieved on: 
Monday, July 17, 2023
Albert Einstein College of Medicine, Patent, Drug development, University, DBA, University of the Chinese Academy of Sciences, Translation studies, LLM, Institute of Botany, Chinese Academy of Sciences, Electrical engineering, MBA, Information, John Marshall Law School, Agilent Technologies, CDMO, Zhejiang University, University of Missouri–St. Louis, CPA, Thermogenesis, United States Patent and Trademark Office, California Southern University, Intellectual property, Suite, Management, Science

The appointments expand ThermoGenesis' Board to seven members.

Key Points: 
  • The appointments expand ThermoGenesis' Board to seven members.
  • Together, their expertise will significantly strengthen our Board of Directors," stated Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis.
  • Previously, from November 2016 to December 2019, Dr. Xu served as a member of ThermoGenesis Holdings, Inc.'s Board of Directors and was a member of the X committee.
  • Dr. Xu received a Master of Science in Electrical Engineering and an MBA from the University of Mississippi, J.D.

Vielight Founder, Dr. Lew Lim Granted a Patent for Artificial Intelligence (AI) Brain Stimulation & Assigns to Vielight Inc.

Retrieved on: 
Thursday, July 13, 2023
Psychiatry, Patent, BCI, Quality of life, Skull, Brain, Research, Magnetic resonance, United States Patent and Trademark Office, EEG, PBM, Artificial intelligence, AI, Medical device, Medical imaging

The patent involves the use of artificial intelligence (AI) to automate intervention with photobiomodulation (PBM) to improve the brain.

Key Points: 
  • The patent involves the use of artificial intelligence (AI) to automate intervention with photobiomodulation (PBM) to improve the brain.
  • It has the potential of resolving challenging psychiatric issues and achieving higher level brain functions.
  • Ongoing research suggests that this method of brain stimulation can produce significant improvement in brain performance without significant negative side effects.
  • “The technology under this patent will take the company to a new level of personalization through the incorporation of AI,” said Dr Lew Lim, Founder & CEO of Vielight.

Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery

Retrieved on: 
Thursday, July 13, 2023
Biotechnology, Practice Management, Health, Pharmaceutical, Oncology, Medical Devices, Research, Infectious Diseases, Hospitals, Surgery, Science, National Center for Telehealth & Technology, Patent, Central nervous system, United States Patent and Trademark Office, NCATS, Traffic barrier, Brain, National Center for Advancing Translational Sciences, CNS, Nose, Development, Cancer pain, Cooperative research and development agreement, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Post-traumatic stress disorder, Dog, Pain management, MET, Toxicology, Nanotechnology, National Institute for Health and Care Excellence, Vaccine

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “Intranasal Delivery” related to its Envelta™product candidate.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “Intranasal Delivery” related to its Envelta™product candidate.
  • Envelta utilizes Molecular Envelope Technology (‘MET’) for the delivery of Enkephalin intranasally for severe cancer pain and non-cancer pain.
  • Nanomerics has licensed its technology to Virpax, which is utilizing the nose-to-brain MET platform to enhance drug delivery for certain of its product candidates including Envelta.
  • “We are pleased with the continued development of our patent portfolio for Envelta,” stated Anthony P. Mack , Chairman and CEO of Virpax.

Dragonfly Energy to be Granted U.S. Patent for Innovative Battery Pack Assembly Design Tailored for Custom Installs

Retrieved on: 
Thursday, July 13, 2023
Patent, United States Patent and Trademark Office, Original equipment manufacturer, Chemistry, RENO, Recreational vehicle, Lithium iron phosphate, Lithium, Electric battery

29/858,079 covering the overall look and design of the assembly case of the Company’s GC3 12V 270Ah LiFePO4 deep cycle battery.

Key Points: 
  • 29/858,079 covering the overall look and design of the assembly case of the Company’s GC3 12V 270Ah LiFePO4 deep cycle battery.
  • The Company believes the design of the GC3 battery pack provides for more flexible solutions and increased energy density compared to traditional lead acid and lithium battery form factors.
  • The Company anticipates the patent will support the Company’s goal to lead the industry in providing safe, affordable and effective energy storage solutions.
  • “Our recently allowed design application helps to ensure that when people see a battery pack with our look and design, they know it represents quality,” Dr. Denis Phares, CEO of Dragonfly Energy, said.

EOS Data Analytics Obtains US Patent for Web-Based Algorithm Generating Crop Productivity Maps

Retrieved on: 
Thursday, July 13, 2023
EOS, Social responsibility, Patent, Noise, Smartphone, Farmer, Agriculture, United States Patent and Trademark Office, Soil, Map, Algorithm, Mathematics, Science and technology in Asia, Food security, Software, Computer data storage, Surveying

The algorithm is implemented in EOSDA Crop Monitoring by EOS Data Analytics. It is designed to automatically process earth observation imagery data and provide agricultural analytics in a web interface.

Key Points: 
  • EOS Data Analytics is powering up EOSDA Crop Monitoring with a patented algorithm for crop productivity maps, giving easy access to precision agritech.
  • Image: EOS Data Analytics
    To view an enhanced version of this graphic, please visit:
    The patent #11,663,753 B1 issued by The United States Patent and Trademark Office on May 30th, 2023 secures a method for generating field productivity maps.
  • The productivity maps proposed by EOS Data Analytics provide a visualized estimation of vegetation trends in a certain geographical area over a given timeframe.
  • Our productivity maps algorithm executes complex computations in a matter of seconds, regardless of the endpoint device's technical specifications.

TPI Composites’ Senior Director of Innovation and Technology, Stephen Nolet is a Contributing Author in “Grand Challenges in the Design, Manufacture, and Operation of Future Wind Turbine Systems”

Retrieved on: 
Tuesday, July 11, 2023
TPI, Innovative Satellite Technology Demonstration Program, Patent, University, Moses Austin, Sandia National Laboratories, National Renewable Energy Laboratory, Principal investigator, Electricity, Innovation, Research, Oak Ridge National Laboratory, Iowa State University, University of Massachusetts Lowell, United States Patent and Trademark Office, Pearson Yachts, Renewable energy, Pharmaceutical industry

SCOTTSDALE, Ariz., July 11, 2023 (GLOBE NEWSWIRE) -- Stephen Nolet, Senior Director of Innovation and Technology at TPI Composites, Inc., (TPI) (Nasdaq: TPIC) is a contributing author in the Wind Energy Science journal’s 2023 “Grand Challenges in the Design, Manufacture, and Operation of Future Wind Turbine Systems” .

Key Points: 
  • SCOTTSDALE, Ariz., July 11, 2023 (GLOBE NEWSWIRE) -- Stephen Nolet, Senior Director of Innovation and Technology at TPI Composites, Inc., (TPI) (Nasdaq: TPIC) is a contributing author in the Wind Energy Science journal’s 2023 “Grand Challenges in the Design, Manufacture, and Operation of Future Wind Turbine Systems” .
  • More than ten industry leaders from across the globe discuss modern wind turbines, future challenges and opportunities on the path to 100% renewable electricity, and what is needed to progress technology towards a lower cost and greater functionality.
  • Mr. Nolet has over 19 years of service with TPI Composites and is a named inventor on more than 35 United States Patent and Trademark Office (USPTO) patents.
  • He has been a Principal Investigator on more than a dozen industry projects with Sandia National Labs, Oak Ridge National Lab, the National Renewable Energy Lab, National and University Industry Consortia, as well as sponsored research with the University of Massachusetts Lowell, the University of Maine, Iowa State University, the University of Tennessee Knoxville, and the University of Texas, Dallas.